Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hemospan versus Voluven in chronic critical limb ischemia
2007-001538-15Phase 2Terminated
- Sponsor
- Sangart
- Start
- Apr 2007
- Modality
- Albumin → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of Hemospan in chronic limb-threatening ischemia (CLTI) (2 arms), sponsored by Sangart. Primary endpoint: Maximum change from baseline in vascular resistance. Started Apr 2007; status: terminated.
02
Drugs
Hemospan
03
Conditions
chronic limb-threatening ischemia (CLTI)
Beyond the preview
Go deeper on 2007-001538-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-001538-15.